Atossa Therapeutics, Inc. (ATOS)
Recent Filing Index
| Form | Filed | Qtr End | F_Period | 8K: Earnings Release |
|---|---|---|---|---|
| 10-QLatest | Q2-2026 | 8-K (2026-08-07) · 99.1 | ||
| 10-Q | Q1-2026 | — | ||
| 10-KLatest | FY-2025 | 8-K (2026-01-09) | ||
| 10-Q | Q3-2025 | 8-K (2025-11-12) · 99.1 | ||
| 10-Q | Q2-2025 | 8-K (2025-08-12) · 99.1 | ||
| 10-Q | Q1-2025 | 8-K (2025-05-13) · 99.1 | ||
| 10-K | FY-2024 | 8-K (2025-03-25) · 99.1 | ||
| 10-Q | Q3-2024 | 8-K (2024-11-12) · 99.1 | ||
| 10-Q | Q2-2024 | 8-K (2024-08-12) · 99.1 | ||
| 10-Q | Q1-2024 | 8-K (2024-05-13) · 99.1 | ||
| 10-K | FY-2023 | 8-K (2024-04-01) · 99.1 | ||
| 10-Q | Q3-2023 | 8-K (2023-11-13) · 99.1 |
Filing Summary
| Report Name | Notes | Fiscal Period (Annual) | Fiscal Period (Quarter) |
|---|---|---|
| Document and Entity Information | ||
| Statements | ||
| Condensed Consolidated Balance Sheets (current Period Unaudited) | — |
|
| Consolidated Balance Sheets | — |
|
| Condensed Consolidated Balance Sheets (current Period Unaudited) (P) | — |
|
| Consolidated Balance Sheets (P) | — |
|
| Condensed Consolidated Statements of Operations (current Period Unaudited) | — |
|
| Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) | — |
|
| Consolidated Consolidated Statements of Operations (current Period Unaudited) | — |
|
| Consolidated Statements of Operations | — |
|
| Condensed Consolidated Statements of Stockholders' Equity (current Period Unaudited) | — |
|
| Consolidated Statements of Stockholders' Equity | ||
| Consolidated Statements of Cash Flows | ||
| Notes | ||
| Accrued Expenses | ||
| Commitments and Contingencies | ||
| Cybersecurity Risk Management, Strategy, and Governance | — |
|
| Defined Contribution Plan | ||
| Fair Value of Financial Instruments | ||
| Going Concern | ||
| Income Taxes | ||
| Insider Trading Arrangements | ||
| Investment In Equity Securities | ||
| Liquidity and Capital Resources | ||
| Nature of Operations | ||
| Net Loss Per Share | ||
| Note 1 | — |
|
| Note 10 | — |
|
| Note 11 | — |
|
| Note 12 | — |
|
| Note 13 | — |
|
| Note 14 | — |
|
| Note 15 | — |
|
| Note 16 | — |
|
| Note 17 | — |
|
| Note 2 | — |
|
| Note 3 | — |
|
| Note 4 | — |
|
| Note 5 | — |
|
| Note 6 | — |
|
| Note 7 | — |
|
| Note 8 | — |
|
| Note 9 | — |
|
| Other Current Liabilities | — |
|
| Pay Vs Performance Disclosure | ||
| Payroll Liabilities | ||
| Prepaid Expenses and Other Current Assets | ||
| Research and Development Rebate Liability | — |
|
| Research and Development Tax Rebate Liability | ||
| Research and Development Tax Rebate Receivable | — |
|
| Segments | ||
| Stock Based Compensation | ||
| Stockholders' Equity | ||
| Subsequent Event | ||
| Summary of Significant Accounting Policies | ||